TRK-IN-31

• Description:

  TRK-IN-31 is an orally active TRK inhibitor with an IC50 of 1.8 nM. TRK-IN-31 has superior antiproliferative activity in the Ba/F3-MPRIP-TRKAG667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 significantly inhibits tumor growth in Ba/F3-MPRIP-TRKAG667C subcutaneous tumor mice model[1].

• UNSPSC:

  12352005

• Target:

  Trk Receptor

• Related Pathways:

  Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  FC1=CC=C (C=C1[C@@H]2N (C3=CNC (C (C (NC4=CC5=C (C=C4) OC (C (N6CCN (CC6) C) =O) =C5) =O) =C3) =O) CCC2) F

• Molecular Formula:

  C30H29F2N5O4

• Molecular Weight:

  561.58

• References & Citations:

  [1]Xu Z, et al. Structural Optimization of Next-Generation TRK Inhibitors against Acquired Drug Resistance Mutations for the Treatment of Solid Tumors. J Med Chem. 2025 Jun 12; 68 (11) :11484-11501.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Trk